PMMA stands for: Poly-Microbial Molecular Assay. It is a new, revolutionary genetic innovation in the management of UTI’s. PMMA is capable of simultaneous identification of 27 different uropathogens and 8 different antibiotic resistant genes. IMD favors this methodology due to it’s more accurate identification of infection at a rate nearly 6 times greater than traditional culture and is proud to offer next day turnaround time on all specimens utilizing this panel.
The Facts
Reasons For Hospitalization
In skilled nursing facilities UTI (urinary tract infection) is the leading cause of:
Infection
ER Admissions
Patient Discomfort and Family Dissatisfaction
Slow turnaround times of current testing (culture & sensitivity)
Delayed treatment causes UTI infection to become Urosepsis
Inaccurate antibiotic treatment
Broad-Based antibiotic treatment leads to ‘natural resistance’ to antibiotics